Inactive Instrument

Acceleron Pharma Inc.

Equities

XLRN

US00434H1086

Biotechnology & Medical Research

Acceleron Pharma Inc. Provides Royalty Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2020

February 04, 2021 at 07:10 am EST

Acceleron Pharma Inc. provided royalty revenue guidance for the fourth quarter and full year ended December 31, 2020. Acceleron expects to report royalty revenue of approximately $23.0 million from net sales of REBLOZYL in the fourth quarter ended December 31, 2020. For the full year 2020, Acceleron expects to report royalty revenue of approximately $54.8 million.

Latest news about Acceleron Pharma Inc.

Global markets live: Airbus, BP, Merck, Pfizer, Meta...	21-12-08
Bristol Myers Squibb Gets FDA Acceptance of sBLA for Reblozyl	21-12-03	DJ
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Biotechnology Index	21-11-22	CI
Merck Completes Acceleron Pharma Acquisition	21-11-22	MT
Merck Completes Cash Tender Offer to Purchase Acceleron Pharma at $180/Share	21-11-22	MT
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from NASDAQ Composite Index	21-11-22	CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Global BMI Index	21-11-22	CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P TMI Index	21-11-22	CI
Acceleron Pharma Inc.(NasdaqGM:XLRN) dropped from S&P Biotechnology Select Industry Index	21-11-22	CI
Merck Completes Tender Offer to Acquire Acceleron Pharma Inc	21-11-19	CI
Merck Sharp & Dohme Corp. completed the acquisition of Acceleron Pharma Inc. from Avoro Capital Advisors LLC, Holocene Advisors, LP, Darwin Global Management Limited and others for $7.1 billion.	21-11-18	CI
Avoro Capital Urges Acceleron Shareholders Not to Tender Into Merck's 'Inadequate' Offer	21-11-17	MT
Merck Extends Tender Offer for Acceleron Pharma	21-11-17	MT
Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-04	CI
Acceleron Pharma Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-04	CI
Earnings Flash (XLRN) ACCELERON PHARMA Reports Q3 Loss $-0.95	21-11-04	MT
Merck Extends FTC Review Period for Acceleron Buyout	21-10-29	MT
Acceleron Pharma Sees Q3 Reblozyl Royalty Revenue at $32 Million Based on Net Sales of $160 Million	21-10-27	MT
Acceleron Pharma Inc. Provides Revenue Guidance for the Third Quarter Ended September 30, 2021	21-10-27	CI
Merck : Bristol-Myers To Shed Acceleron Stake Ahead Of Merck & Co.'s $11.5 Billion Acquisition	21-10-21	MT
Merck : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Company	21-10-14	MT
Acceleron Pharma : Holocene Advisors says Merck's offer undervalues Acceleron	21-10-13	RE
Acceleron Pharma : Holocene Advisors says Merck's offer undervalues Acceleron	21-10-13	RE
Merck : Launches Tender Offer to Buy Acceleron Pharma at $180 Per Share	21-10-12	MT
ACCELERON PHARMA : Jefferies Starts Acceleron Pharma at Hold With $180 Price Target	21-10-07	MT

Chart Acceleron Pharma Inc.

Duration

Period

More charts

Company Profile

Acceleron Pharma Inc. is a biopharmaceutical company. It is focused on discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on natural regulators of cellular growth and repair, mainly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. Its therapeutic areas include pulmonary and hematology. Its pulmonary program, Sotatercept, is a receptor type IIA fusion protein that is used for the treatment of patients with pulmonary arterial hypertension (PAH). ACE-1334 is a wholly owned TGF-beta superfamily-based ligand trap designed to bind and inhibit TGF-beta 1 and 3 ligands but not TGF-beta 2. Its REBLOZYL (luspatercept-aamt), is an erythroid maturation agent designed to promote red blood cell (RBC). It generates multiple Fc-fusion protein ligand traps, IntelliTrap platform technology and a pipeline of clinical and preclinical therapeutic candidates targeting mechanisms underlying serious and rare diseases.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	106B
ARGENX SE	+7.02%	23.47B
BIONTECH SE	-14.60%	21.9B
GENMAB A/S	-7.05%	18.77B
WUXI APPTEC CO., LTD.	-38.55%	17.85B
BEIGENE, LTD.	-8.83%	16.78B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	14.41B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.86B
VIKING THERAPEUTICS, INC.	+329.39%	8.78B

Bio Therapeutic Drugs